# Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

> **NCT01776684** · NA · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- EGFR Mutation Positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** EGFR TKIs (gefitinib, erlotinib, afatinib, et al)

## Key facts

- **NCT ID:** NCT01776684
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2014-05
- **Final completion:** 2015-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01776684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01776684, "Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01776684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*